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Abstract
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, characterized primarily by the
loss of dopaminergic neurons in substantia nigra. The pathogenic mechanisms of PD remain unclear, and no effective
therapy currently exists to stop neurodegeneration in this debilitating disease. The identification of mutations in
mitochondrial serine/threonine kinase PINK1 or E3 ubiquitin-protein ligase parkin as the cause of autosomal recessive
PD opens up new avenues for uncovering neuroprotective pathways and PD pathogenic mechanisms. Recent studies
reveal that PINK1 translocates to the outer mitochondrial membrane in response to mitochondrial depolarization and
phosphorylates ubiquitin at the residue Ser65. The phosphorylated ubiquitin serves as a signal for activating parkin and
recruiting autophagy receptors to promote clearance of damaged mitochondria via mitophagy. Emerging evidence
has begun to indicate a link between impaired ubiquitin phosphorylation-dependent mitophagy and PD pathogenesis
and supports the potential of Ser65-phosphorylated ubiquitin as a biomarker for PD. The new mechanistic insights and
phenotypic screens have identified multiple potential therapeutic targets for PD drug discovery. This review highlights
recent advances in understanding ubiquitin phosphorylation in mitochondrial quality control and PD pathogenesis and
discusses how these findings can be translated into novel approaches for PD diagnostic and therapeutic development.
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Background
Parkinson’s disease (PD) is the most common neuro-
degenerative movement disorder with a prevalence of
about 1 % at the age of 65 and of 4 %–5 % by the age of
85 [1, 2]. The disease occurs either in relatively rare,
familial forms or in common, sporadic forms [3]. The
different forms of PD share similar motor symptoms of
rigidity, bradykinesia, postural instability, and resting
tremor, which appear when there is a loss of 50 %–60 %
of dopaminergic neurons in the substantia nigra pars
compacta. Increasing evidence indicates that neuro-
degeneration is more widespread and occurs in multiple
regions in the brain [4, 5]. The etiology of PD, particu-
larly sporadic PD cases, is unknown, and there is no
reliable biomarker for PD diagnosis. Current medica-
tions for PD only provide temporary relief of motor
symptoms with no disease-modifying activity to delay or
stop disease progression [3, 6]. Thus, there is clearly a
need to develop new diagnostic approaches and more
effective therapeutics for PD.
Although familial forms of PD account for less than
10 % of PD cases, the discovery of genes responsible for
familial PD cases has provided insights into pathogenic
mechanisms leading to neurodegeneration in PD. For
example, the identification of loss-of-function mutations
in mitochondrial serine/threonine kinase PINK1 as a
cause of familial PD [7–9] provides genetic evidence for
an involvement of mitochondrial dysfunction in PD
pathogenesis. The finding of loss-of-function mutations
in E3 ubiquitin-protein ligase parkin as a cause of
familial PD [9–11] indicates a role of ubiquitination
dysregulation in PD pathogenesis. Ubiquitination is a
dynamic post-translational modification in which
ubiquitin, a 76-amino-acid polypeptide, is conjugated to a
lysine residue in substrate proteins through coordinated
* Correspondence: LLI5@emory.edu
Department of Pharmacology and Center for Neurodegenerative Disease,
Emory University School of Medicine, Atlanta, GA 30322, USA
© 2015 Chin and Li. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chin and Li Translational Neurodegeneration  (2016) 5:1 
DOI 10.1186/s40035-015-0049-6
sequential actions of E1 ubiquitin-activating enzyme, E2
ubiquitin-conjugating enzyme, and E3 ubiquitin-protein
ligase [12]. Proteins can be either monoubiquitinated or
polyubiquitinated via successive conjugation of additional
ubiquitin molecules to one of the seven internal lysine
residues in the preceding ubiquitin. The different types of
ubiquitination play distinct signaling roles in regulation of
diverse cellular processes by modulating protein activity,
localization, trafficking, or degradation [13, 14]. Ubiquitin-
dependent signalling is also modulated by deubiquitinating
enzymes, which catalyze the removal of ubiquitin from
proteins [15]. Recent phosphoproteomic studies revealed
that ubiquitin itself can be phosphorylated [16–18], adding
a new layer of control over the ubiquitin signalling system.
Interestingly, PINK1 was identified as a ubiquitin kinase for
phosphorylation of ubiquitin, and the phosphorylated
ubiquitin was shown to play novel signaling roles in activat-
ing parkin and recruiting autophagy receptors to promote
mitophagy. In this review, we will summarize recent
findings on the roles of ubiquitin phosphorylation in
mitochondrial quality control and PD pathogenesis. We will
also discuss the potential of ubiquitin phosphorylation as a
PD biomarker and the strategies to target ubiquitin
phosphorylation-dependent mitophagy for PD therapeutic
intervention.
PINK1 phosphorylates ubiquitin at Ser65 in response to
mitochondrial depolarization
Mitochondria are double membrane-bound organelles
with four distinct submitochondrial compartments: the
outer mitochondrial membrane (OMM), the inner mito-
chondrial membrane (IMM), the intermembrane space
(IMS), and the matrix. The compartmentalization is crucial
to mitochondria-mediated processes, including energy
production, metabolism, redox control, calcium homeosta-
sis, and programmed cell death [19, 20]. Mitochondrial
dysfunction is implicated as a key factor in PD pathogenesis
[21–23]. Human genetic studies revealed that homozygous
mutations in mitochondrial kinase PINK1 cause autosomal
recessive, early-onset PD [7–9, 24], whereas heterozygous
mutations in PINK1 increase the risk for developing
late-onset PD [25–27], highlighting the importance of
knowing the sites and mechanisms of PINK1 action.
PINK1 is an ubiquitously expressed, 581-amino-acid
protein Ser/Thr kinase with an N-terminal mitochondrial
targeting sequence [28]. Under normal physiological con-
ditions, PINK1 is imported into healthy mitochondria
through the translocase of outer membrane (TOM) and
translocase of inner membrane (TIM) complexes [29],
where the 64-kDa full-length PINK1 can undergo sequen-
tial proteolytic cleavages by the matrix-localized mitochon-
drial processing peptidase (MPP) and the IMM-localized
protease PARL to generate a 52-kDa processed form of
PINK1 [30–33]. According to one model, the 52-kDa
processed form of PINK1 is retrotranslocated to the
cytosol for rapid degradation by the proteasome through
the N-end rule pathway [34] and consequently, PINK1
protein levels are virtually undetectable under normal
conditions, thus arguing against a function of PINK1 in
healthy mitochondria [30, 34, 35]. In contrast, other
studies reported significant levels of PINK1 protein under
normal conditions, but localized PINK1 to either the
OMM with its kinase domain facing the cytoplasm
[36–38] or to the IMM/IMS with its kinase domain facing
the IMS [39–43]. Recently, super-resolution imaging
analyses using three-dimensional structured illumination
microscopy (3D-SIM) [44] or a combination of tracking
and localization microscopy (TALM) and fluorescence
photoactivation localization microscopy (F-PALM) [45]
clearly showed that, under normal conditions, PINK1 is
not present on the OMM of healthy mitochondria, but
rather PINK1 resides in the IMM/IMS where it is mainly
localized to the cristae membrane and intracristae space.
Furthermore, PINK1 was found to colocalize with the
mitochondrial chaperone TRAP1, a previously identified
PINK1 substrate [40, 46], in these submitochondrial com-
partments [44]. Together, these results support a model
(Fig. 1) that PINK1 plays an intramitochondrial signaling
role by phosphorylating TRAP1 [40] and potentially also
other IMM/IMS-localized proteins, such as the complex I
subunit NdufA10 [47] and the mitochondrial serine
protease HtrA2 [48], to regulate activities of polarized
mitochondria.
Super-resolution imaging analyses showed that, in re-
sponse to mitochondrial depolarization, PINK1 changes
its submitochondrial localization from the IMM/IMS to
the OMM of depolarized mitochondria [44, 45], whereas
TRAP remains in the IMM/IMS [44]. The PINK1
localization on the OMM of depolarized mitochondria is
likely due to the blockade of PINK1 mitochondrial im-
port through the IMM by the loss of mitochondrial
membrane potential [29]. As expected, the mitochon-
drial import blockade prevents the cleavage of PINK1 by
PARL, leading to accumulation of full-length PINK1 on
damage mitochondria [29, 30, 33]. Recently, accumula-
tion of misfolded proteins in the mitochondrial matrix
was reported to cause PINK1 localization on the OMM
without mitochondrial depolarization [49], which might be
explained by the possibility that misfolded proteins may
somehow inhibit PINK1 mitochondrial import through
the TIM complex. Increasing evidence supports that mito-
chondrial dysfunction-triggered PINK1 localization on the
OMM serves as a damage-sensing, quality-control mech-
anism to mark damaged mitochondria for clearance by
mitophagy [29, 35, 44, 49, 50].
Mitochondrial depolarization not only causes PINK1
localization on the OMM of damaged mitochondria but
also induces PINK1 dimerization and autophosphorylation
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at its Ser228 and Ser402 residues [51, 52], which could be
an activation mechanism for enhancing PINK1 kinase ac-
tivity [53]. Intriguingly, PINK1 was recently found to phos-
phorylate the residue Ser65 of either ubiquitin [54–57] or
ubiquitin chains conjugated to mitochondrial proteins in
response to mitochondrial depolarization [57, 58], indicat-
ing a function of PINK1 as a ubiquitin kinase. This finding
is very exciting because previous phosphoproteomic ana-
lyses revealed that ubiquitin can be phosphorylated at
multiple sites, including Ser65 [16, 17, 59], but the identity
of the kinases for phosphorylating ubiquitin was unknown.
Quantitative proteomic analysis showed that, under
normal conditions, the Ser65-phosphorylated form of
ubiquitin (phospho-Ser65-ubiquitin) is essentially un-
detectable on healthy mitochondria, but upon mitochon-
drial depolarization, the level of phospho-Ser65-ubiquitin
increases to ~20 % of the total ubiquitin level on damaged
mitochondria [57], indicating ubiquitin phosphorylation at
Ser65 is a stress-responsive signal that can be induced by
mitochondrial dysfunction. Interestingly, a study in yeast
[18] demonstrated that ubiquitin phosphorylation at Ser65
can also be induced by oxidative stress, although another
kinase must be involved because no PINK1 orthologue
exists in yeast. Emerging data indicate that ubiquitin phos-
phorylation at Ser65 causes significant changes in the
structures of ubiquitin and ubiquitin chains and affects
ubiquitination and deubiquitination cascades catalyzed by
a number of E2 ubiquitin-conjugating enzymes, E3 ligases,
and deubiquitinating enzymes [18, 60]. Thus, ubiquitin
phosphorylation can have a profound impact on the ubi-
quitin signalling system. Below, we will focus on the role
of PINK1-mediated ubiquitin phosphorylation in activat-
ing parkin to promote mitophagy.
Ser65-phosphorylated ubiquitin activates parkin and
recruits autophagy receptors on damaged mitochondria
to promote mitophagy
There has been intense interest in understanding parkin-
regulated neuroprotective processes because loss-of-
function mutations in parkin are a major cause of familial
PD [9–11] and oxidative/nitrosative stress-induced dam-
age to parkin is associated with sporadic PD [61–63].
Parkin is a 465-amino-acid, cytosolic E3 ubiquitin-protein
ligase with an N-terminal ubiquitin-like (Ubl) domain and
four zinc-binding domains, RING0, RING1, IBR (in-
between RING), and RING2 [64]. Parkin is expressed in
many tissues and cell types, where it localizes in the
cytosol under normal physiological conditions [10, 11].
Drosophila genetic studies provided first evidence that
parkin functions downstream of PINK1 in a common
pathway involved in the maintenances of mitochondrial
homeostasis [65, 66]. Subsequent studies in mammalian
cells showed that PINK1 is required for recruiting parkin
from the cytosol to depolarized mitochondria to promote
mitophagy [35, 37, 50, 67, 68]. Biochemical analyses
revealed that parkin is a PINK1 substrate and identified
the residue Ser65 within the Ubl domain of Parkin as the
phosphorylation site by PINK1 [69–71].
Convergent data from recent studies support a model
that PINK1-mediated ubiquitin phosphorylation and parkin
phosphorylation work in concert to activate parkin and re-
cruit autophagy receptors to promote mitophagy (Fig. 2).
Fig. 1 PINK1-mediated intramitochondrial signaling in healthy mitochondria. PINK1 is imported into healthy mitochondria through the TOM and
TIM complexes and is then cleaved sequentially by mitochondrial processing peptidase (MPP) and PARL to generate a processed form of PINK1
that resides in the intermembrane space. There, PINK1 can phosphorylate mitochondrial chaperone TRAP1 and perhaps also other substrates to
regulate the activities of polarized mitochondria, such as respiration and redox control
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Mitochondrial dysfunction triggers PINK1 localization
and activation on the OMM of damaged mitochondria
[29, 35, 44, 49, 50], resulting in Ser65-phosphorylation of
ubiquitin chains that are already conjugated to OMM pro-
teins by a yet unidentified E3 ligase(s) [51–53]. A function
of Ser65-phosphorylated ubiquitin is to serve as a parkin
receptor for binding and recruiting parkin from the cyto-
sol to the OMM of damaged mitochondria [58]. Ser65-
phosphorylated ubiquitin also functions as an allosteric
activator of parkin E3 ligase activity [72–75]. Structural
analyses showed that parkin normally exists in an inactive
or autoinhibited conformation [64, 76] and that binding of
Ser65-phosphorylated ubiquitin to parkin causes a sub-
stantial conformational change in parkin, which together
with Ser65-phosphorylation parkin Ubl domain, converts
parkin from the inactive conformation to an active
conformation [72–75]. Once activated, parkin is able to
ubiquitinate many OMM proteins [77, 78], which in turn
provide additional substrates for phosphorylation by
PINK1, leading to further recruitment and activation of
parkin, thereby acting as a positive-feedback amplification
mechanism to dramatically increase the local concentra-
tion of Ser65-phosphorylated ubiquitin on damaged mito-
chondria [57, 79]. In addition, Ser65-phosphorylated
ubiquitin chains are resistant to deubiquitination by many
deubiquitinating enzymes, including USP15 and USP30
[60], thereby further contributing to the accumulation of
Ser65-phosphorylated ubiquitin on damaged mitochon-
dria. Importantly, a recent study showed that the Ser65-
phosphorylated ubiquitin on damaged mitochondria
serves as a signal for recruiting autophagy receptors, such
as optineurin (OPTN) and NDP52, which then recruit the
components of the autophagy machinery to promote au-
tophagic clearance of damaged mitochondria [80].
Dysregulation of ubiquitin phosphorylation in PD
pathogenesis
Human genetic studies have identified numerous PD-
causing, homozygous mutations in PINK1 and parkin,
which are distributed throughout all domains of these
two proteins [7–11]. Recent evidence from studying
PD-linked PINK1 and parkin mutations indicates that
impairment in ubiquitin phosphorylation-dependent
mitochondrial quality control is critically involved in PD
pathogenesis. A number of PD-linked mutations found
in the PINK1 kinase domain, such as PINK1 G309D,
L347P, C388R, and G409V mutations, have been shown
to abolish the kinase activity of PINK1 for phosphorylat-
ing its substrates and the ability of PINK1 to promote
parkin recruitment [40, 69, 81, 82], indicating that
mutation-induced loss of PINK1 catalytic activity is a
mechanism leading to impaired mitophagy and neurode-
generation. In addition, PD-linked C92F and W437X
mutations which are located outside of the PINK1 kinase
domain were recently shown to impair the ability of
PINK1 to localize on the OMM of depolarized mito-
chondria [44], indicating that mutation-induced loss of
mitochondrial damage-sensing function of PINK1 is
Fig. 2 PINK1-mediated phosphorylation of ubiquitin and parkin on damaged mitochondria in facilitation of mitophagy. Mitochondrial damage causes
PINK1 localization and activation on the OMM, leading to Ser65-phosphorylation of pre-existing ubiquitin chains conjugated to OMM proteins (1). The
phosphorylated ubiquitin recruits parkin, enables Ser65-phosphorylation of parkin by PINK1, and activates parkin (2). The activated parkin ubiquitinates
additional OMM proteins (3) and thus provides more substrates for phosphorylation by PINK1 (4), leading to further recruitment and activation of parkin
(2). This positive feed-forward cycle results in a rapid increase in the local concentration of Ser65-phosphorylated ubiquitin (5), which serves as a signal
for recruiting autophagy receptors, such as OPTN and NDP52, to promote mitophagy (6)
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another mechanism that triggers impaired mitochondrial
quality control. In parkin, PD-linked L283P mutation
found in the phospho-Ser65-ubiquitin-binding interface
has been shown to impair parkin recruitment and activa-
tion on depolarized mitochondria [72–75], indicating that
mutation-induced loss of phospho-Ser65-ubiquitin-bind-
ing ability of parkin can also lead to impaired mitochon-
drial quality control and neurodegeneration. Furthermore,
a number of PD-linked mutations found in the parkin E3
ligase domain, such as parkin T240R and G430D muta-
tions, are able to disrupt the E3 ligase activity of parkin for
ubiquitinating its substrates and the ability of parkin to
promote mitophagy [35, 50, 68], indicating that mutation-
induced loss of parkin catalytic activity is another mechan-
ism that causes impaired mitochondrial quality control
and familial PD pathogenesis.
Human genetic studies have also identified a number of
heterozygous mutations in PINK1 and parkin as risk fac-
tors for developing late-onset PD [9, 25–27]. In addition,
oxidative damage to parkin has been detected in brains
from patients with sporadic PD [61–63]. These findings
suggest that dysregulation of PINK1/parkin-mediated,
ubiquitin phosphorylation-dependent mitochondrial qual-
ity control may also contribute to the pathogenesis of
sporadic PD.
Ubiquitin phosphorylation as a potential biomarker for
PD diagnosis
A major challenge in the PD field is to identify bio-
markers for PD diagnosis, particularly at the early stage
of the disease. The recent finding of a link between ubi-
quitin phosphorylation and PD pathogenesis suggests
the possibility of using phospho-Ser65-ubiquitin as a po-
tential PD biomarker. One approach for detecting
phospho-Ser65-ubiquitin is to use anti-phospho-Ser65-
ubiquitin antibodies that specifically recognize the
Ser65-phosphorylated form of ubiquitin but not the
non-phosphorylated form of ubiquitin. Such antibodies
have recently been generated and used for analyses of
human postmortem brain samples to show the accumu-
lation of phospho-Ser65-ubiquitin in cytoplasmic gran-
ules that were localized adjacent to, but not within the
Lewy bodies and Lewy neurites - the pathological hall-
marks of PD [83]. The phospho-Ser65-ubiquitin-positive
granules were partially co-localized with mitochondrial
and lysosomal markers [83], suggesting that phospho-
Ser65-ubiquitin was accumulated in damaged mitochon-
dria and/or in autolysosomes containing damaged mito-
chondria, perhaps as a result of increased mitochondrial
damage and/or impaired mitophagy. The phospho-Ser65-
ubiquitin-positive granules appear to increase with aging
and sporadic PD [83], providing support for the potential
of phospho-Ser65-ubiquitin as a biomarker for PD.
In addition to the anti-phospho-Ser65-ubiquitin antibody
approach, a sensitive, quantitative proteomic approach was
recently developed to measure the levels of phospho-
Ser65-ubiquitin in cell and tissue lysates [57, 79, 84]. This
approach has been used to show increased brain levels of
phospho-Ser65-ubiquitin in a mouse model of mitochon-
dria dysfunction caused by enhanced mitochondrial DNA
mutagenic stress [84], indicating that accumulation of
phospho-Ser65-ubiquitin could occur as a result of in-
creased mitochondrial damage in vivo. The sensitivity and
quantitative nature of the proteomic approach are particu-
larly useful for its further development as a diagnostic tool
for PD.
Targeting ubiquitin phosphorylation-dependent mito-
phagy for PD therapeutic development
Recent advances in understanding ubiquitin
phosphorylation-dependent mitochondrial quality con-
trol have identified several potential targets for thera-
peutic intervention in PD. An attractive therapeutic
target is the PINK1 kinase activity because PINK1-
mediated phosphorylation of ubiquitin and other sub-
strates is critically involved in neuroprotection against
mitochondrial dysfunction [40, 54–56, 69, 85]. A novel
PINK1-targeting approach was recently developed,
which uses the ATP analogue kinetin triphosphate
(KTP) or the KTP precursor kinetin to enhance the kin-
ase activity of PINK1 [46]. Augmentation of PINK1 kin-
ase activity by KTP or kinetin is able to promote parkin
recruitment to damaged mitochondria and enhance cel-
lular defense against oxidative stress-induced apoptosis
[46], providing support for the therapeutic potential of
PINK1 activation in PD treatment.
The E3 ubiquitin-protein ligase activity of parkin is an-
other potential target for PD therapeutic development.
The finding of phospho-Ser65-ubiquitin as an allosteric
activator of parkin E3 ligase activity [72–75] that dis-
rupts the autoinhibited conformation of parkin [64, 76]
provides structural information for the development of
small molecules that mimic the effect of phospho-Ser65-
ubiquitin to activate parkin-dependent mitophagy. In
addition, a recent study reported that parkin recruitment
to damaged mitochondria is positively regulated by the
deubiquitinating enzyme USP8 through its action to re-
move K6-linked ubiquitin chains from parkin [86], sug-
gesting that USP8 activation could be another approach
to promote clearance of damaged mitochondria. Fur-
thermore, emerging data indicate that parkin-mediated
mitochondrial protein ubiquitination and mitophagy are
negatively regulated by deubiquitinating enzymes USP15
[87] and USP30 [88], which catalyze the removal of of
ubiquitin from parkin substrates on damaged mitochon-
dria. Knockdown of endogenous USP15 or USP30 is able
to ameliorate mitochondrial and motor behavioral
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defects in parkin-deficient flies [87, 88] and enhance
neuroprotection against paraquat toxicity [88], suggest-
ing that USP15 and USP30 inhibition could provide
potential therapeutic benefits for treating PD.
Phenotypic screening for chemical or genetic modifiers
of PINK1 or parkin mutant phenotypes has emerged as
a useful approach for PD drug discovery. Recent screens
of a 2000-compound library using fibroblast cells from
PD patients carrying parkin mutations have identified 15
compounds that can rescue mitochondrial dysfunction
phenotypes of parkin-mutant patient cells [89]. Two of
these compounds, ursocholanic acid and ursodeoxy-
cholic acid, were further characterized and shown to
ameliorate mitochondrial functional defects in parkin-
mutant patient fibroblasts as well as in LRRK2-mutant
patient fibroblasts, by acting through the glucocorticoid
receptor and Akt signalling [89]. In addition, a Drosoph-
ila genetic screen using PINK1-deficient flies has identi-
fied UBIAD1/Heix, an enzyme involved in the synthesis
of vitamin K2, as a modifier of PINK1 mutant phenotype
[90]. Further analyses showed that vitamin K2 is able to
improve the defective mitochondrial and behavioral
phenotypes of PINK1 and parkin mutant flies, by acting
as an electron carrier downstream of complex I [90].
These results support the therapeutic potential of
vitamin K2 supplementation in PD treatment.
Conclusions
An exciting, recent breakthrough from studying PD-
linked proteins PINK1 and parkin is the discovery of a
novel neuroprotective pathway in which PINK1 phos-
phorylates ubiquitin to activate parkin and promote
mitophagy for maintaining mitochondrial and neuronal
homeostasis. Emerging evidence has begun to indicate a
link between the impairment of this neuroprotective
pathway and the pathogenesis of familial PD as well as
sporadic PD. These new mechanistic insights have re-
vealed promising, novel avenues for PD diagnostic
development and therapeutic intervention. Recent work
supports the development of phospho-Ser65-ubiquitin
as a potential biomarker for PD, and future studies using
the quantitative proteomic approach [79, 84] to analyze
phospho-Ser65-ubiquitin levels in PD patient samples,
particularly in easily accessible body fluids such as blood
or urine, should be pursued actively. In addition, newly
gained insights into ubiquitin phosphorylation-dependent
mitochondrial quality control have identified a number of
potential therapeutic targets, which could be used in
high-throughput screening for PD drug discovery. Fur-
thermore, phenotypic screens for chemical or genetic
modifiers of PINK1 and parkin mutant phenotypes have
generated promising hits [89, 90], and future phenotypic
screens using induced pluripotent stem cells (iPSCs) from
PD patients will facilitate the development of new
therapeutics to combat mitochondrial dysfunction and
neurodegeneration in PD.
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